Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
David N. Fisman et al.
Summary: Research in Ontario, Canada, showed that new variants of concern (VOCs) of SARS-CoV-2 have higher risks of hospitalization, ICU admission, and death compared to non-VOC strains, with the Delta variant showing the most pronounced increase in risk.
CANADIAN MEDICAL ASSOCIATION JOURNAL
(2021)
Article
Medicine, General & Internal
S. F. Lumley et al.
Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jennifer M. Dan et al.
Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.
Article
Medicine, General & Internal
Stefan Pilz et al.
Summary: According to the study in Austria, the rate of SARS-CoV-2 re-infections is relatively low. Protection against SARS-CoV-2 after natural infection is comparable to the highest estimates of vaccine efficacies.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Biochemistry & Molecular Biology
Koen B. Pouwels et al.
Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Mario Plebani
Article
Immunology
Megan M. Sheehan et al.
Summary: The study found that prior infection in patients with COVID-19 provided a high level of protection against reinfection and symptomatic disease, with this protection increasing over time. This suggests that viral shedding or ongoing immune response may persist beyond 90 days, and may not necessarily represent true reinfection.
CLINICAL INFECTIOUS DISEASES
(2021)
Editorial Material
Medicine, General & Internal
Rachel Wilf-Miron et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.
Article
Infectious Diseases
Jeffrey P. Townsend et al.
Summary: This study estimates the time to reinfection of SARS-CoV-2 using data from coronavirus relatives, finding that the protection period is shorter compared to other human-infecting coronaviruses. This information is crucial for public health decision-making.
Article
Public, Environmental & Occupational Health
Rebecca K. Borchering et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Editorial Material
Medicine, General & Internal
Carlos del Rio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Psychology, Developmental
Sally H. Adams et al.
Summary: Based on the March 2021 data, most unvaccinated young adults in the US express an intention to receive COVID-19 vaccines, but 24% remain hesitant. Common reasons for hesitancy include concerns about vaccine safety and side effects, as well as the belief that others are in greater need of the vaccine.
JOURNAL OF ADOLESCENT HEALTH
(2021)
Editorial Material
Public, Environmental & Occupational Health
Pragya D. Yadav et al.
JOURNAL OF TRAVEL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.
Editorial Material
Medicine, General & Internal
Jennifer Block
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Public, Environmental & Occupational Health
Eunice Twumwaa Tagoe et al.
Summary: The development of COVID-19 vaccines does not mean the end of the pandemic, as countries need to purchase enough doses and successfully roll out vaccination plans. Low- and middle-income countries may encounter more challenges in vaccine distribution, but with strategies to overcome barriers and expand vaccination programs, successful rollout can be achieved.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Endocrinology & Metabolism
A. V. Raveendran et al.
Summary: Long COVID refers to the persistence of symptoms in individuals who have recovered from SARS-CoV-2 infection, possibly related to organ damage, post viral syndrome, etc. Clinical evaluation should focus on identifying the pathophysiology and appropriate remedial measures.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
(2021)
Article
Medicine, General & Internal
Laith J. Abu-Raddad et al.
Summary: The study shows that reinfection is rare in Qatar's young and international population, with natural infection providing strong protection against reinfection with an estimated efficacy of around 95% for at least seven months. Reinfections are often less severe than primary infections.
Article
Multidisciplinary Sciences
Jung Ki Kim et al.
Article
Immunology
Paul Fine et al.
CLINICAL INFECTIOUS DISEASES
(2011)
